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Colon cancers are composed of phenotypically heterogeneous tumor cell subpopulations
with variable expression of putative stem cell and differentiation antigens. While in normal
colonic mucosa, clonal repopulation occurs along differentiation gradients from crypt base
toward crypt apex, the clonal architecture of colon cancer and the relevance of tumor cell
subpopulations for clonal outgrowth are poorly understood. Using a multicolor lineage tracing
approach in colon cancer xenografts that reﬂect primary colon cancer architecture, we here
demonstrate that clonal outgrowth is mainly driven by tumor cells located at the leading
tumor edge with clonal axis formation toward the tumor center. While our ﬁndings are
compatible with lineage outgrowth in a cancer stem cell model, they suggest that in color-
ectal cancer tumor cell position may be more important for clonal outgrowth than tumor cell
phenotype.
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Colorectal cancer derives from normal colonic mucosa bystepwise accumulation of mutations that transform epi-thelial cells into invasively growing tumors. Normal
colonic mucosa is quite simply organized, basically as a sheet of
epithelial cells with infoldings forming stereotypical crypts. These
are continuously clonally repopulated by stem cells from the crypt
base with maturation toward the crypt apex1. In contrast to
normal colonic mucosa, the architecture of colon cancer is much
less understood since these tumors form masses with varying
degrees of morphologically disarrayed epithelial glands2. How-
ever, colon cancers do not appear to be completely unorganized.
Gradients from less differentiated tumor cells at the leading
tumor edge to glandular differentiated tumor cells in the tumor
center can be observed in many cases, and mimic the polarity of
normal colonic crypts to varying extent3, 4. However, in contrast
to normal colonic crypts, such gradients in colon cancer are not
situated within stereotypical morphological units and some colon
cancers even lack differentiation gradients. Therefore, the rele-
vance of phenotypically distinct tumor cells for tumor growth and
the resulting colon cancer architecture remains incompletely
understood.
Colon cancer cell subpopulations with distinct phenotypes and
degrees of differentiation may have different functions. Most
prominently, tumor initiating potential has been attributed to
colon cancer cells with high WNT and MAPK signaling activity5,
6. In well-differentiated colon cancers, such tumor cells are fre-
quently located close to the inﬁltrative tumor edge, leading to the
hypothesis that colon cancer stem cells reside at this location7.
However, deﬁning colon cancer stem cells through tumor-
initiating potential, the current gold standard, may have certain
limitations and cannot always be generalized8, 9. Moreover, it has
been questioned whether the position of a cell within the cellular
hierarchy of a growing tumor is adequately reﬂected by tumor-
initiating potential10. Therefore, from these data, the role of
distinct tumor cell phenotypes for the dynamics of clonal
expansion in colon cancer has remained unclear.
Recently, lineage tracing tools have been developed that allow
assessing cell fate restriction in temporal order, and were used to
deﬁne clonal dynamics in genetically engineered mouse tumor
models11, 12. Moreover, current studies demonstrated clonal
outgrowth from colon cancer cells with high MAPK activity or
expression of the WNT target gene LGR5, and thus provided
direct evidence for a cellular hierarchy emanating from these
tumor cell subsets in vivo13, 14. Here we used a phenotype-
independent multicolor lineage tracing system for quantitative
cell fate analysis in colon cancer xenografts. We demonstrate that
clonal expansion starts at the leading tumor edge, where tumor
cells compete for outgrowth toward the tumor center, where
clones may be lost due to tumor necrosis. Our ﬁndings suggest
that tumor cell position may be more important for lineage
persistence than tumor cell phenotype. This new concept may
have implications for the cancer stem cell hypothesis and for the
design of therapeutic strategies.
Results
Tumor cell differentiation gradients in colon cancer. First, we
assessed primary colon cancers for the expression of nuclear β-
catenin and FRA1 as surrogate markers for high WNT and
MAPK signaling15, 16 that were previously linked to tumor-
initiating potential and colon cancer stem cells. In addition, we
determined expression of CK20 and GLUT1 that in contrast
indicated epithelial cell differentiation and hypoxia, respec-
tively17, 18. Many colon cancers showed increased nuclear
β-catenin and FRA1 expression in tumor cells located at the
inﬁltrative tumor edge, whereas CK20 and GLUT1 were most
strongly expressed in the tumor center, often close to necrotic
areas, suggesting a polarity with differentiation gradients directed
from the tumor edge toward the tumor center (Fig. 1a, b and
Supplementary Fig. 1). However, a substantial number of colon
cancers did not show deﬁnite intratumoral differentiation gra-
dients, since they either expressed these markers more diffusely
throughout the tumor, or were negative for individual markers
(Fig. 1a, b and Supplementary Fig. 1). These ﬁndings suggested
that colon cancers may be categorized into tumors with polarized
or more diffuse expression of differentiation antigens and mar-
kers that were previously related to colon cancer stem cells
(Fig. 1c).
Next, we characterized a collection of colon cancer xenografts
and found that SW1222-derived tumors showed a polarized
distribution of nuclear β-catenin, FRA1, CK20, and GLUT1, while
HCT116 colon cancer xenografts showed more diffuse marker
expression and lack of differentiation gradients (Fig. 1d). We
therefore used xenografts of these two cell lines as model tumors
for the typical spectrum of presence or absence of differentiation
gradients that is observed in primary colon cancers.
Multicolor lineage tracing in colon cancer in vivo. In order to
visualize lineage outgrowth in colon cancer, we developed a
lentiviral Cre recombinase sensitive reporter system that allowed
stochastic expression of different ﬂuorescent colors in individual
tumor cells. Our system consists of three lentiviral vectors, two of
which mediate doxycycline-inducible expression of an estrogen
receptor-Cre fusion protein (pLenti rtTA3G and pLenti TetO-
CreERT2). Upon Cre recombination, the third vector, similar to a
Brainbow transgene19, randomly switches from expression of
orange to either tagged red, yellow, or blue ﬂuorescence proteins
(pLenti Multicolor, Fig. 2a). This doxycycline and tamoxifen-
controlled design was completely devoid of unwanted back-
ground recombination. We then transduced all three vectors into
SW1222 and HCT116 colon cancer cells, expanded single cell
clones, and xenografted them into immune compromised NOD/
SCID mice (Fig. 2b). After xenograft growth, we induced
recombination by doxycycline and tamoxifen treatment and
analyzed clonal outgrowth over time (Fig. 2c). Three days after
induction of recombination, individual or small clusters of colon
cancer cells were randomly labeled by different ﬂuorescent colors
in a mosaic pattern throughout SW1222 and HCT116 xenograft
tumors. Of note, integration of multiple vectors resulted in var-
ious mixed ﬂuorescent colors (Supplementary Fig. 2). Interest-
ingly, at this early time point after recombination, we already
observed loss of few color-labeled clones into the central tumor
necrosis (Fig. 2d). Ten days after recombination, single color
clones had increased in size, while at 31 days after recombination,
large stripe- and wedge-like shaped clones extended from the
tumor edge to the necrotic tumor center (Fig. 2d and Supple-
mentary Fig. 3). Inducible multicolor tracing thus allowed us to
monitor clonal outgrowth within human colon cancer in vivo,
and suggested clonal expansion along axes from the tumor edge
toward the tumor center.
Clone characteristics in colon cancer. To characterize the shape
and architecture of colon cancer subclones in more detail, we
determined the coordinates of coherent tumor cells with identical
colors relative to perpendicular linear axes from the tumor edge
to the tumor center (Fig. 3a). An adapted model for linear
regression analyses revealed that 31 days after recombination
most clones had expanded in a linear manner in SW1222 and
HCT116 xenografts, while we observed this with less signiﬁcance
at earlier time points (Fig. 3b). Moreover, when we determined
the angles (α) of lines ﬁtted to clones by linear regression relative
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to tangents to the leading tumor edge (Fig. 3a), these pre-
dominantly centered around 90° in tumors of both cell lines
(Fig. 3c). In addition, we then performed BrdU tracing experi-
ments and found that within 6 or 7 days after a single BrdU pulse,
the label progressed from the tumor edge toward the tumor
center (Supplementary Fig. 4). Collectively, these ﬁndings pro-
vided evidence of a non-random linear expansion of tumor cell
clones, perpendicular to the leading tumor edge and directed
toward the tumor center.
With these ﬁndings in mind, we analyzed the distribution of
nuclear β-catenin, FRA1, CK20, and GLUT1 within individual
clones. As expected for SW1222-derived xenografts, nuclear
β-catenin and FRA1 marked tumor cells predominantly at the
leading tumor edge, while CK20 and GLUT1 marked cells close to
the necrotic tumor center within these clones, indicating clonal
axis formation along the polarity of the centripetal differentiation
axis in these tumors (Fig. 3d). Importantly however, since clonal
axes in HCT116 colon cancer xenografts also were perpendicular
to the leading tumor edge, and all four markers were diffusely
expressed in individual clones of these tumors, this indicated that
clonal axis formation does not generally parallel or depend on
differentiation gradients (Fig. 3d, e). These ﬁndings suggested
limited inﬂuence of differentiation gradients on clonal architec-
ture and outgrowth in colon cancer.
Clonal dynamics in colon cancer. To further learn about clonal
dynamics in colon cancer xenografts, we analyzed clone sizes and
clonal density after multicolor labeling over time. Three days after
recombination, clones were composed of two–three cells in
average. Clone sizes then increased exponentially until 17 days
with subsequently slightly slowed growth rates (Fig. 4a).
Accordingly, clonal density, i.e., the number of clones per area,
decreased over time. Importantly, when comparing clonal density
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Fig. 1 Varying degrees of differentiation gradients in colon cancer. a Immunohistochemistry for indicated proteins in representative primary colon cancers
demonstrates examples of polarized or diffuse marker distribution. b Frequencies of observed marker distributions in colon cancer (n= 92). c Schematic
model for colon cancers with polarized or diffuse marker distribution. d Immunohistochemistry for indicated proteins in SW1222- and HCT116-derived
xenografts demonstrates polarized or diffuse marker expression, respectively. All micrographs show tumors from leading tumor edge (image bottom) to
tumor center or central tumor necrosis (image top). Arrowheads indicate positively stained tumor cells. Scale bars, 100 µm
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at the tumor edge and in the tumor center, we observed a sig-
niﬁcantly earlier decrease in clonal density at the leading tumor
edge, most obvious at 10 days and 17 days after recombination in
both SW1222 and HCT116 colon cancer xenografts (Fig. 4a).
Also, over time the average clonal width at the leading tumor
edge increased when adjusted to increases in tumor
circumference (Supplementary Fig. 5). Together with the obser-
vation that clones could be lost due to central tumor necrosis,
these ﬁndings suggested a clonal competition at the leading tumor
edge with subsequent clonal outgrowth toward the tumor center.
Of note, when we analyzed individual clones 31 days after
recombination for cancer hot spot mutations, no mutational
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Fig. 2 Multicolor lineage tracing in colon cancer xenografts. a Lentiviral vectors for expression of rtTA (pLenti rtTA3G), doxycycline-dependent CreERT2
(pLenti TetO-CreERT2), and the Cre-responsive multicolor transgene (pLenti Multicolor). Upon Cre-recombination, transgene elements ﬂanked by loxN,
lox2272, or loxP sites will be removed at random, causing an irreversible switch from expression of orange (OFP) to tagged red (RFP-FLAG), yellow (YFP-
V5), or blue ﬂuorescent proteins (BFP-VSV), respectively. LTR long terminal repeat, TRE tetracycline response element, BlastR/PuroR blasticidin and
puromycin resistance genes. PRE posttranscriptional regulatory element. b Triple transduced colon cancer cells were xenografted into NOD/SCID mice. c
Schedule for doxycycline (DOX) and tamoxifen (TAM) treatment, and tumor harvest after xenografting. d Confocal immune ﬂuorescence for RFP-FLAG
(red), YFP-V5 (green), and BFP-VSV (blue) in xenografts at indicated time points after tamoxifen-induced multicolor labeling. Individual clones at 31 days
are indicated by dotted lines. Fluorescent images show xenograft tumors from leading tumor edge (image bottom) to central tumor necrosis (image top).
Arrowheads indicate loss of tumor cell clones into tumor necrosis. Scale bars, 50 µm
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differences were observed. This indicated that clonal outgrowth
and competition likely occurred in the absence of overt changes
in driver mutation proﬁles (Supplementary Table 1).
Finally, we inferred a two-dimensional spatial simulation
model for clonal dynamics in colon cancer (Supplementary
Data 1), implementing few rules only that we derived from our
in vivo observations (Fig. 4b). First, clones may only be lost into
the tumor center or into central tumor necrosis, represented by
the upper border of our square model. Second, clonal competition
by lateral clone expansion may only occur at the leading tumor
edge, represented by the lower border of the model. Third, based
on the measurements of proliferation by Ki67 in primary colon
cancers (n= 92) and xenograft tumors (Supplementary Fig. 6),
growth rates in our model were slowed to 0.5 in central tumor
areas relative to the leading tumor edge. This model, when
composed of few “cells” only, illustrated rapid loss of individual
tumor cells and a drift toward mono-clonality (Fig. 4b). In larger
scale, linear expansion of tumor cell clones from the leading
tumor edge toward the tumor center were seen with widening of
some clones and inevitable loss of those that lost contact to the
leading edge, causing a continuous drift toward oligoclonality,
and well ﬁtting our in vivo ﬁndings (Fig. 4c). Also, the dynamics
of gains in clone size and loss in clone density over time
quantitatively matched our observations in colon cancer
xenografts (Fig. 4d). Importantly, this also included an earlier
decrease of clonal density at the leading tumor edge compared to
the tumor center, which was due to the implemented restriction
of clonal competition to the leading tumor edge. Collectively, this
model corroborated the idea that the in vivo observed clonal
outgrowth from the leading tumor edge toward the tumor center
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Fig. 3 Shape and axis formation of colon cancer subclones. a Schematic illustration of clonal analysis. Positions of cells in individual clones relative to
leading tumor edge and tumor center were determined. For each clone, a line of best ﬁt for cell positions was calculated by linear regression, yielding a
clonal axis. α indicates the angle of the clonal axis relative to the leading tumor edge. b Signiﬁcance (P values of linear regression) of linear alignment of
cells in individual clones of different sizes at indicated time points after multicolor labeling. c Angles (α) of clonal axes relative to the leading tumor edge at
indicated time points after multicolor labeling. d Confocal images show positions of indicated stem cell and differentiation antigens (red) in individual
clones (green) of colon cancer xenografts. Fluorescent images show xenograft tumors from leading tumor edge (image bottom) to central tumor necrosis
(image top). Scale bars, 50 µm. e Schematic model suggesting identical clonal outgrowth in colon cancers with polarized and diffuse marker distribution
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may be based on few rather positional characteristics of colon
cancer cells while differentiation gradients and polarity may be of
less importance.
Discussion
In this study, we implemented a quantitative lineage tracing
strategy to gain insights into the clonal expansion dynamics of
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Fig. 4 Analysis and simulation of clonal dynamics in colon cancer. a Clone sizes (left panels) and clones per area (right panels), as determined by analysis of
confocal ﬂuorescence images of SW1222 and HCT116 colon cancer xenografts at different time points after multicolor labeling. Clones per area were measured
overall and separately in tumor thirds close to the tumor edge and close to the tumor center, as indicated. Data are mean and error bars indicate s.e.m. (left
panels) and s.d. (right panels). ***P<0.001 and **P< 0.01 indicate differences between tumor edge and tumor center by two-sided t-test. b Two-dimensional
simulation model for clonal dynamics. Bottom row simulates tumor cells at the tumor edge and top row simulates tumor cells neighboring central tumor
necrosis. At the tumor edge, cells divide during each simulated replication cycle and probabilities for cell expansion upwards P(U), to the left P(L) or to the right
P(R) are equal. In other positions, cells divide upwards at decreased frequency with P(U)=0.5. One possible outcome after four replication cycles is illustrated.
c Scaling this model to 60 × 60 cells simulates clones expanding from tumor edge to tumor center. One possible outcome after 30 replication cycles is shown.
d Average clone sizes (left panel) and clones per area (right panel) from 100 independent simulations. Clones per area are given overall, and in thirds of the
model close to tumor edge and tumor center, respectively. Gray lines approximately deliminate simulation segments ﬁtting our in vivo data
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individual tumor cells within growing colon cancer in vivo. We
used cell line-derived colon cancer xenografts as model tumors to
reproduce the architecture, cellular composition, and differ-
entiation of primary human colon cancers4. Our data suggest that
colon cancer cells at the leading tumor edge compete for clonal
outgrowth, which is directed toward the tumor center. In tumors
with polarized differentiation gradients, this clonal expansion
may coincide with tumor cell differentiation. These ﬁndings are
in agreement with recent data demonstrating clonal outgrowth
from tumor cells with high MAPK pathway activity or high
expression of the WNT target gene LGR5 at the leading tumor
edge13, 14. In this case, linear expansion of tumor cell subclones
may be well compatible with lineage outgrowth from phenoty-
pically deﬁned colon cancer stem cells10. Despite a distorted
architecture, clonal outgrowth and differentiation in colon cancer
therefore can be reminiscent of normal colonic mucosa, where
stem cells at the crypt base compete for clonal repopulation of
individual crypts1.
However, colon cancer xenografts lacking differentiation gra-
dients, and thus more diffusely distributed expression of putative
stem cell and differentiation antigens, unexpectedly showed the
same pattern of clonal expansion from tumor edge to center.
Therefore, clonal ﬁtness and positive clonal selection rather
appear to depend on positioning of tumor cells at the leading
tumor edge than on tumor cell differentiation. Indeed, when
considering broad expression of some putative cancer stem cell
antigens in colon cancers, it may be difﬁcult to imagine how a
cancer stem cell that is trapped centrally within the tumor mass
should efﬁciently compete for space and resources required for
clonal expansion20, 21. Based on our data, and supported by the
results of our simulation model, which implemented position as
the only factor determining tumor cell behavior, we therefore
propose that competition of colon cancer cells for clonal expan-
sion is mainly restricted to the leading tumor edge. The pheno-
type of tumor cells within expanding clones may still be variable,
depending on the individual genetic background of the tumor,
and may secondarily be inﬂuenced by a position-related tumor
microenvironment3, 5.
Previous attempts to follow individually labeled tumor cells
over time, independently of their phenotype, either used murine
models, or lentiviral color- or bar-coding methods for random
genetic labeling of tumor cells in vitro before xenotransplantation
into mice22–24. While the approach in murine models is not
applicable to human malignancies, the in vitro labeling approach
has the caveat that clonal cell tracing cannot be induced after
secondary tumor architectures have formed, and thus precludes
access to clonal fate data of individual tumor cells. By combining
the advantages of inducible clonal cell tracing and lentiviral
delivery, we overcome these restrictions, and for the ﬁrst time
demonstrate a constant drift toward oligoclonality within colon
cancer that appears to be based on clonal competition and axial
outgrowth. However, although we simulate these dynamics in our
simulation model by neutral stochastic competition of tumor cells
at the leading tumor edge, the biological basis for clonal com-
petition yet remains to be determined. Also, due to a limited
number of different ﬂuorescent colors, some aspects including the
signiﬁcance of neighboring clones with identical colors or clone
fragmentation during outgrowth may be missed by our labeling
strategy and require further study.
Importantly, in our model, clonal competition does not depend
on mutational evolution. Although additionally acquired muta-
tions in individual tumor cell subclones may provide ﬁtness
advantage, genetic changes that substantially alter the clonal
composition of a ﬁnal tumor are assumed to be rare events in
rapidly expanding cell populations25. An inferred “Big Bang”
model of colon cancer evolution therefore suggested that clonal
dynamics in established tumors are mainly devoid of substantial
mutational evolution26. In line with this idea, we found no dif-
ferences in driver mutation proﬁles of individual tumor cell
subclones. Therefore, we suggest that clonal competition in colon
cancer is mainly determined by tumor cell position and may
continuously occur throughout the lifespan of a tumor. Never-
theless, it remains to be determined to what extent other heritable
traits may have an impact on clonal architecture and growth
dynamics, since others reported epigenetic differences among
subclones of colonic adenomas and colon cancers27, 28.
In contrast to unperturbed tumor growth, mutational evolution
certainly plays an important role in acquired resistance to tar-
geted therapy29. Previous data suggested that treatment protocols
stabilizing tumor growth rather than attempting to eradicate the
tumor may prolong cancer survival30. Our data suggesting con-
tinuous clonal competition may explain such ﬁndings. If
treatment-resistant tumor subclones have to compete for space
and resources with treatment-sensitive subclones that may prevail
under gentle targeted therapy, loss of resistant clones due to
necrosis in the tumor center may occur by chance. In contrast,
harsher-targeted therapy may eliminate sensitive tumor cell
clones and strongly favor quick outgrowth of resistant clones with
earlier treatment failure. This hypothesis, however, will require
further experimental proof, and may then inform the design of
future-targeted therapeutic approaches for patients with color-
ectal cancer.
Methods
Tumor specimens, immunohistochemistry and immune ﬂuorescence. Colon
cancer specimens from patients that underwent surgical resection at the University
of Munich (LMU) were drawn from the archives of the Institute of Pathology.
Specimens were anonymized, and the need for consent was waived by the insti-
tutional ethics committee of the Medical Faculty of the LMU. Immunohis-
tochemistry was done on 5 µm tissue sections of primary cancer specimens or
xenograft tumors, as previously described4, using the antibodies listed in Supple-
mentary Table 2. Stained slides were then inspected by light microscopy for the
distribution of each marker antigen and categorized as negative, polarized if
expression gradients from leading tumor edge to tumor center were observed, or
diffuse if such gradients were absent. Ki67 proliferation was separately assessed at
the leading tumor edge and in the tumor center. Relative BrdU staining intensity
was quantiﬁed continuously from leading tumor edge to tumor center using ImageJ
(NIH). For immune ﬂuorescence, 5 µm sections of xenograft tumors were depar-
afﬁnized and antigens were retrieved in Target Retrieval Solution (Dako) for 20
min in a microwave oven. Sections were then incubated with primary antibodies
listed in Supplementary Table 2. Secondary Alexa Fluor 405-, 488-, and 555-
conjugated antibodies were used for visualization, and for some experiments nuclei
were counterstained with DAPI (Vector Laboratories). Confocal ﬂuorescence
images were taken on a LSM 700 laser scanning microscope using the ZEN soft-
ware (Zeiss).
Lentiviral vectors. All template plasmids were obtained through Addgene (www.
addgene.org). For the inducible pLenti TetO-CreERT2 expression vector, we
ampliﬁed CreERT2 from pCAG-CreERT2 (a gift from Connie Cepko) by PCR, and
inserted it between BamH1 and Xba1 restriction sites of pLenti CMVTRE3G eGFP
Puro (a gift from Eric Campeau), replacing eGFP by CreERT2. For the Cre-
sensitive recombination vector pLenti Multicolor, we ﬁrst PCR-ampliﬁed expres-
sion cassettes for Kusabira orange, mCherry, and EYFP from CMV-Brainbow 1.1
M30, and EBFP2 from pEBFP2-Nuc (a gift from Robert Campbell), using primers
that omitted membrane or nuclear localization signals, respectively. Amplicons
then were inserted into EcoRV sites of pcDNA3.1 (Invitrogen), and the 3′ ends of
mCherry, EYFP, and EBFP2 were replaced from BsrG1 to Not1 restriction sites by
synthetic sequences that added FLAG, V5, or VSV tags, respectively. Kusabira
orange and tagged ﬂuorescent color coding genes were then sequentially inserted
into a plasmid with synthetic paired loxN, lox2272, and loxP sites. The whole
expression cassette was then inserted between Age1 and Sal1 sites of pLenti PGK-
GFP (a gift from Didier Trono), replacing GFP. Finally, the PGK promoter was
replaced by an EF1α promoter, yielding pLenti Multicolor. Vector elements were
veriﬁed by restriction analysis and sequencing.
Cell culture and lentiviral transductions. HEK293 and HCT116 cells were
obtained from ATCC and SW1222 from the Ludwig Institute for Cancer Research
(New York, USA). Cell lines were authenticated using short-tandem repeat pro-
ﬁling, tested negative for mycoplasma contamination and cultured in Dulbecco’s
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modiﬁed Eagle medium (DMEM) supplemented with 10% FBS, 100 U/ml peni-
cillin, and 0.1 mg/ml streptomycin (Biochrom). For transductions, lentivirus was
produced in HEK293 cells by co-transfection with lentiviral vector, pCMV-dR8.91,
and pMD2.G, as previously described8. Virus containing medium was passed
through 0.45 µm ﬁlters (Millipore), mixed 1:1 with DMEM, and used to infect
HCT116 and SW1222 colon cancer cells in the presence of 8 µg/ml polybrene
(Sigma-Aldrich). pLenti rtTA3G, pLenti TetO-CreERT2, and pLenti Multicolor
triple transduced cells were then single cell subcloned by limiting dilution,
expanded, and tested for recombination in vitro by addition of 1 µg/ml doxycycline
and 10 µM 4-hydroxytamoxifen (Sigma-Aldrich), before xenotransplantation into
mice.
Tumor xenografts. Mouse experiments were reviewed and approved by the
Regierung von Oberbayern. A total of 1 × 106 single clone-expanded SW1222 or
HCT116 colon cancer cells carrying the multicolor lineage tracing constructs were
suspended in 100 μl of a 1:1 mixture of PBS and growth factor-depleted Matrigel
(Corning), and injected subcutaneously into 6–8-week-old male NOD/SCID mice
(NOD.CB17-Prkdcscid, The Jackson Laboratory) for xenograft formation. When
tumor diameters reached 7 mm, recombination of pLenti Multicolor transgenes
was induced by 1 mg doxycycline p.o. for 3 consecutive days, followed by 3 mg
tamoxifen i.p. (Sigma-Aldrich). For BrdU tracing, mice were injected once with a
1.25 mg BrdU pulse. At distinct time points, mice were killed, tumors were
removed, formalin ﬁxed, and parafﬁn embedded for further analyses.
Panel sequencing. For next-generation panel sequencing, we used the Ion
AmpliSeq Cancer Hotspot Panel v2, covering the mutational status of 50 onco-
genes and tumor suppressor genes, according to the manufacturer’s protocol (Life
Technologies). Thirty-one days after recombination, individual clones from
immunohistochemically stained slides of different SW1222 and HCT116 xenograft
tumors were microdissected and 1–5 ng DNA were used as template for library
construction. Multiplexed libraries were then sequenced on an Ion Personal
Genome Machine (Thermo Fisher). Reads were mapped to human reference
genome hg19 and ﬁltered for non-synonymous variants.
Analysis of clone characteristics. To determine clone sizes, we counted neigh-
boring tumor cells with identical ﬂuorescent colors on confocal images. For each
clone, we then determined the positions of each cell C (xC, yC), as well as the closest
positions of leading tumor edge E (xE, yE) and tumor necrosis N (xN, yN) using
ImageJ (NIH). By geometric shifting and rotation, we then transformed coordi-
nates so that E′ (0, 0) and N′ (xN′, yN′) with xN′= yN′. The resulting cell positions
C′ (xC′, yC′) for each clone were then analyzed for linear correlation by t-test, the
slope of the linear regression m was determined, and the angle θ of the line of best
ﬁt with the x-axis was calculated by θ= tan−1(m). The angle α of each clone relative
to a tangent to the leading tumor edge then resulted from α= θ + 45°.
Simulation model and code availability. The two-dimensional spatial simulation
model for clonal dynamics was implemented in VBA-Excel (code available in
Supplementary Data 1). In a worksheet “Clones”, simulating 60 × 60 cells, random
numbers from 1 to 3600 were distributed. These are illustrated in a 60 × 60 matrix
in worksheet “Graphics” with 10 different colors, determined by clone number
modulo 10. For each simulation cycle for cells at the bottom row, representing the
leading tumor edge, each cell content is either copied to the neighboring cell on the
left or right, simulating lateral expansion for clonal competition, or to the cell
above, simulating clonal outgrowth toward the tumor center. This behavior is
determined at random. For all remaining cells, contents are copied to the cell
above, while this is restricted to every Nth row, with N simulating the proliferation
gradient from leading tumor edge (bottom row) to tumor center (other rows).
Contents of cells that are to be replaced are shifted to cells immediately above,
causing loss of clones only at the top row of the model, which simulates loss into
tumor necrosis. Frequencies are recorded in worksheet “Numbers” and represented
in a diagram in worksheet “Graphics”.
Statistical analysis. Sample sizes were based on preliminary data and previous
experience. Xenograft bearing mice were randomly assigned to groups with dif-
ferent observation time points after multicolor recombination, and no xenografts
were excluded from analysis. Investigators were not blinded to group allocations.
Appropriate statistical tests were used to compare data with similar variances and
are referenced in ﬁgure legends. Biological replicates are given as n values. All
graphs show mean and error bars represent standard deviation (s.d.) or standard
error of the mean (s.e.m.). Differences were considered statistically signiﬁcant when
P< 0.05, and P values are given within ﬁgures or ﬁgure legends. Statistics were
calculated with GraphPad Prism.
Data availability. Data from genetic mutation analyses are given in Supplementary
Table 1. All other data are available from the corresponding author on reasonable
request.
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